 NASDAQ: KZIA, an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center MSK in New York, NY will investigate the potential use of Kazias investigational new drug, GDC-0084, in combination with radiotherapy in a phase I clinical trial for cancer that has spread to the brain brain metastases and leptomeningeal metastases. This research will explore a new use of GDC-0084 and will run concurrently with other ongoing studies in different forms of brain cancer. 